Astrazeneca (AZN) Times Interest Earned (2009 - 2026)
Astrazeneca (AZN) recorded quarterly Times Interest Earned of -$10.8 in Q1 2026, down 75.59% quarter-over-quarter from -$6.15 in Q4 2025, and down 2.63% on a YoY basis from -$11.1 in Q1 2025.
Astrazeneca (AZN) Times Interest Earned (2009 - 2026) Analysis & Trends
Astrazeneca's Times Interest Earned history runs 18 years deep, the most recent figure standing at -$10.8 for Q1 2026.
- In Q1 2026, Times Interest Earned fell 2.63% year-over-year to -$10.8; the TTM figure through Mar 2026 stood at -$8.18 (down 29.96% YoY), while the FY2025 annual figure was $8.11, up 41.28% from the prior year.
- Times Interest Earned was -$10.8 for Q1 2026 at Astrazeneca, down from -$6.15 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$1.73 in Q2 2022 to a low of -$10.8 in Q1 2026.
- Historically, Times Interest Earned has averaged -$5.78 across 5 years, with a median of -$5.7 in 2023.
- Biggest YoY gain for Times Interest Earned was 49.87% in 2022; the steepest drop was 449.68% in 2022.
- A 5-year view of Times Interest Earned shows it stood at -$3.04 in 2022, then rose by 8.75% to -$2.77 in 2023, then tumbled by 71.15% to -$4.75 in 2024, then retreated by 29.65% to -$6.15 in 2025, then tumbled by 75.59% to -$10.8 in 2026.
- The last three Times Interest Earned figures came in at -$10.8 (Q1 2026), -$6.15 (Q4 2025), and -$8.26 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -13.73 |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn | -10.80 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.80 |
| Dec 31, 2025 | -6.15 |
| Sep 30, 2025 | -8.26 |
| Jun 30, 2025 | -7.99 |
| Mar 31, 2025 | -10.53 |
| Dec 31, 2024 | -4.75 |
| Sep 30, 2024 | -4.61 |
| Jun 30, 2024 | -6.20 |
| Mar 31, 2024 | -7.54 |
| Dec 31, 2023 | -2.77 |
| Sep 30, 2023 | -4.98 |
| Jun 30, 2023 | -5.70 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -3.04 |
| Sep 30, 2022 | -3.67 |
| Jun 30, 2022 | -1.73 |
| Mar 31, 2022 | -2.61 |
| Dec 31, 2021 | 0.87 |
| Sep 30, 2021 | 5.00 |
| Jun 30, 2021 | -3.46 |